# Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix

> **NCT02346227** · PHASE3 · COMPLETED · sponsor: **Jean-Pierre Van geertruyden** · enrollment: 327 (actual)

## Conditions studied

- Uterine Cervical Dysplasia
- Papillomavirus Infections

## Interventions

- **DRUG:** AV2
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02346227
- **Lead sponsor:** Jean-Pierre Van geertruyden
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2018-08
- **Final completion:** 2018-08
- **Target enrollment:** 327 (ACTUAL)
- **Last updated:** 2018-10-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02346227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02346227, "Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02346227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*